Changing concepts in multiple myeloma: From conventional chemotherapy to high-dose treatment

European Journal of Cancer

Volumn 39, Issue 1, 2003, Pages 9-18

  Sonneveld, P ^a   Segeren, C M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Multiple myeloma; Stem cell transplantation

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; M PROTEIN; MELPHALAN; PREDNISONE; VINCRISTINE;

AGED; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME 13; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; INTERMETHOD COMPARISON; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; REVIEW; SEPSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037216149     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00503-8     Document Type: Article

References (88)

1. Gahrton. Multiple myeloma. Arnold, 1996.
2. Kyle R.A. "Benign" monoclonal gammopathy - after 20-35 years of follow-up. Mayo Clin Proc. 68:1993;26-36.
3. Kyle R.A., Rajkumar S.V. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am. 13:1999;1181-1202.
4. San Miguel J.F., Blade Creixenti J., Garcia-Sanz R. Treatment of multiple myeloma. Hematologica. 84:1999;36-58.
5. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36:1975;842-854.
6. Osgood E. Survival time of patients with plasmacytic myeloma. Cancer Chaemother Rep. 9:1960;1-10.
7. Alexanian R., Haut A., Khan A.U.et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. Jama. 208:1969;1680-1685.
8. Alexanian R., Bonnet J., Gehan E. et al. Combination chemotherapy for multiple myeloma. Cancer. 30:1972;382-389.
9. Gregory W.M., Richards M.A., Malpas J.S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma. an overview of published trials [see comments] J Clin Oncol. 10:1992;334-342.
10. Group M.T.C. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma. an overview of patients from 27 randomised trials Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998:6633;16. (12):3832-3842.
11. McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983:8354;2. 822-824.
12. Attal M., Harousseau J.L., Stoppa A.M. et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [see comments]. N Engl J Med. 335:1996;91-97.
13. Proposed guidelines for protocol studies. I. Introduction. II. Plasma cell myeloma. 3. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia. Cancer Chaemother Rep [3] 1973;4(1):141-173.
14. Durie B.G., Russell D.H., Salmon S.E. Reappraisal of plateau phase in myeloma. Lancet. 1980:8185;2. 65-68.
15. MacLennan I.C., Chapman C., Dunn J., Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults [see comments]. Lancet. 339:1992;200-205.
16. Samson D., Gaminara E., Newland A.et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma [see comments]. Lancet. 2:1989;882-885.
17. Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 102:1998;1115-1123.
18. Gerard C.J., Olsson K., Ramanathan R., Reading C., Hanania E.G. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res. 58:1998;3957-3964.
19. Corradini P., Voena C., Tarella C. et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 17:1999;208-215.
20. Konigsberg R., Zojer N., Ackermann J. et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 18:2000;804-812.
21. Zojer N., Konigsberg R., Ackermann J. et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Blood. 95:2000;1925-1930.
22. Tricot G., Jagannath S., Vesole D. et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 85:1995;588-596.
23. Tricot G., Sawyer J.R., Jagannath S. et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 15:1997;2659-2666.
24. Desikan R., Barlogie B., Sawyer J. et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities [In Process Citation]. Blood. 95:2000;4008-4010.
25. Facon T., Avet-Loiseau H., Guillerm G.et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2- microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 97:2001;1566-1571.
26. Case D.C. Jr., Lee D.J.d., Clarkson B.D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 63:1977;897-903.
27. Blade J., San Miguel J.F., Alcala A. et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomised multicentric study of 487 patients. J Clin Oncol. 11:1993;1165-1171.
28. Salmon S.E., Haut A., Bonnet J.D. et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1:1983;453-461.
29. Boccadoro M., Marmont F., Tribalto M. et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol. 9:1991;444-448.
30. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 310:1984;1353-1356.
31. Alexanian R., Barlogie B., Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 33:1990;86-89.
32. Anderson H., Scarffe J.H., Ranson M. et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 71:1995;326-330.
33. Alexanian R., Dimopoulos M.A., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 80:1992;887-890.
34. Lokhorst H.M., Sonneveld P., Cornelissen J.J. et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant. 23:1999;317-322.
35. Barlogie B., Jagannath S., Desikan K.R. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 93:1999;55-65.
36. Alexanian R., Barlogie B., Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 105:1986;8-11.
37. Lokhorst H.M., Meuwissen O.J., Bast E.J., Dekker A.W. VAD chemotherapy for refractory multiple myeloma. Br J Haematol. 71:1989;25-30.
38. Blade J., San Miguel J., Sanz-Sanz M.A. et al. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD). Eur J Cancer. 1:1992;57-60.
39. Bonnet J., Alexanian R., Salmon S.et al. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer Treat Rep. 66:1982;1267-1271.
40. Mineur P., Menard J.F., Le Loet X. et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol. 103:1998;512-517.
41. Dimopoulos M.A., Weber D., Kantarjian H., Delasalle K.B., Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 52:1996;77-81.
42. Barlogie B., Velasquez W.S., Alexanian R., Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol. 7:1989;1514-1517.
43. Salmon S.E., Dalton W.S., Grogan T.M. et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chaemosensitizer. Blood. 78:1991;44-50.
44. Cornelissen J.J., Sonneveld P., Schoester M. et al. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol. 12:1994;115-119.
45. Sonneveld P., Durie B.G., Lokhorst H.M. et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON [see comments]. Lancet. 340:1992;255-259.
46. Singhal S., Mehta J., Desikan R. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1999;1565-1571.
47. Selby P.J., McElwain T.J., Nandi A.C. et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 66:1987;55-62.
48. Cunningham D., Paz-Ares L., Gore M.E. et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol. 12:1994;764-768.
49. Segeren C.M., Sonneveld P., van der Holt B.et al. Myeloablative treatment following intensified chemotherapy in untreated multiple myeloma: a prospective randomised phase III study. Blood. 98:2001;815a.
50. Barlogie B., Jagannath S., Dixon D.O. et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood. 76:1990;677-680.
51. Moreau P., Fiere D., Bezwoda W.R. et al. Prospective randomised placebo-controlled study of granulocyte- macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol. 15:1997;660-666.
52. Lokhorst H.M., Sonneveld P., Wijermans P.W. et al. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol. 92:1996;44-48.
53. Palumbo A., Triolo S., Argentino C. et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood. 94:1999;1248-1253.
54. Cunningham D., Paz-Ares L., Milan S. et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 12:1994;759-763.
55. Lenhoff S., Hjorth M., Holmberg E.et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 95:2000;7-11.
56. Alexanian R., Dimopoulos M., Smith T., Delasalle K., Barlogie B., Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood. 83:1994;512-516.
57. Rajkumar S.V., Fonseca R., Lacy M.Q. et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 23:1999;1267-1272.
58. Vesole D.H., Barlogie B., Jagannath S. et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 84:1994;950-956.
59. Fermand J.P., Ravaud P., Chevret S. et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomised clinical trial. Blood. 92:1998;3131-3136.
60. Tricot G., Jagannath S., Vesole D.H., Crowley J., Barlogie B. Relapse of multiple myeloma after autologous transplantation. survival after salvage therapy Bone Marrow Transplant. 16:1995;7-11.
61. Fermand J.P., Levy Y., Gerota J. et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 73:1989;20-23.
62. Goldschmidt H., Hegenbart U., Wallmeier M. et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma (see comments). Ann Oncol. 8:1997;243-246.
63. Lahuerta J.J., Martinez-Lopez J., Grande C. et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the spanish registry for transplantation in multiple myeloma. Br J Haematol. 109:2000;138-147.
64. Bjorkstrand B, Hagman A, Ljungman P, et al. Autologous stem cell transplantation in multiple myeloma-an update of the EBMT registry. In: VIIIth International Myeloma Workshop. Banff, Canada; 2001. p. 141.
65. Moreau P., Facon T., Attal M. et al. Superiority of 200 mg/m2 melphalan (HDM200) over 8 GY total body irradiation plus 140 mg/m2 melphalan (TBI and HDM140) as conditioning regimen for peripheral blood stem cell (PBSC) transplantation in patients with newly diagnosed multiple myeloma (MM). Final analysis of the IFM9502 randomised trial. Blood. 99:2002;731-735.
66. Fermand JP, Levy V, Ravaud P, et al. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD-34 enriched ABSC: preliminary results of a two by two designed randomised trial in 230 young patients with multiple myeloma. In: VIIIth International Myeloma Workshop; 2001; Banff, Canada. p. 147.
67. Harousseau J.L., Attal M., Divine M. et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood. 85:1995;3077-3085.
68. Blade J., San Miguel J.F., Fontanillas M. et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol. 14:1996;2167-2173.
69. Barlogie B., Jagannath S., Vesole D.H. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 89:1997;789-793.
70. Attal M, Harousseau JL, Facon T, et al. Single versus double transplant in myeloma: a randomised trial of the "Inter Groupe Francais du Myelome" (IFM). 1999;94(10):714a.
71. Attal M, Harousseau J-L. Autologous peripheral blood progenitor cell transplantation for multiple myeloma: Balliere's Tindall; 1999.
72. Harousseau J.L., Milpied N., Laporte J.P. et al. Double-intensive therapy in high-risk multiple myeloma. Blood. 79:1992;2827-2833.
73. Weaver C.H., Zhen B., Schwartzberg L.S. et al. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant. 22:1998;245-251.
74. Attal M., Harousseau J.L., Michaux J.L. et al. Single versus double transplant in myeloma: a randomised trial of the Inter Groupe Franccophone du Myelome (IFM). Blood. 96:2000;557a.
75. Attal M, Harousseau JL, Facon T. Single versus double transplant in multiple myeloma: a randomised trail of the "Inter Groupe Francais Du Myelome" (IFM). In: VIIIth International Myeloma Workshop. Banff, Canada; 2001. p. 28.
76. Cavo M, Tosi P, Zamagni E, et al. The "Bologna 96″ clinical trial of single versus double PBSC transplantation for previously untreated MM:results of an interim analysis. In: VIIIth International Myeloma Workshop; 2001; Banff, Canada; 2001. p. 29-30.
77. Attal M., Huguet F., Schlaifer D. et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 79:1992;1130-1136.
78. Jagannath S., Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematol Oncol Clin North Am. 6:1992;437-449.
79. Alexanian R., Dimopoulos M.A., Hester J., Delasalle K., Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 84:1994;4278-4282.
80. Bjorkstrand B.B., Ljungman P., Svensson H. et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 88:1996;4711-4718.
81. Cunningham D., Powles R., Malpas J. et al. A randomised trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 102:1998;495-502.
82. Boccadoro M., Tarella C., Palumbo A. et al. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy (see comments). Haematologica. 84:1999;905-910.
83. Fermand J.P., Chevret S., Ravaud P. et al. High-dose chaemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood. 82:1993;2005-2009.
84. Majolino I., Vignetti M., Meloni G. et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica. 84:1999;844-852.
85. Marit G., Faberes C., Pico J.L. et al. Autologous peripheral-blood progenitor-cell support following high- dosechemotherapy or chaemoradiotherapy in patients with high-risk multiple myeloma. J Clin Oncol. 14:1996;1306-1313.
86. Alegre A., Diaz-Mediavilla J., San-Miguel J. et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant. 21:1998;133-140.
87. Gianni A.M., Tarella C., Bregni M. et al. High-dose sequential chaemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol. 12:1994;503-509.
88. Bjorkstrand B., Ljungman P., Bird J.M., Samson D., Gahrton G. Double high-dose chaemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant. 15:1995;367-371.